Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19999725 | 0.89 | NAAA (0.42) | PDE4BCSNK2BCSNK2A1FAAH | |
| SCHEMBL4515994 | 0.83 | SIGMAR1 (0.47) | KDM4EALDH1A1CSNK2BCSNK2A1KMT2A | |
| SCHEMBL4510525 | 0.83 | SIGMAR1 (0.47) | KDM4EALDH1A1CSNK2BCSNK2A1KMT2A | |
| SCHEMBL4685201 | 0.83 | SIGMAR1 (0.47) | KDM4EALDH1A1CSNK2BCSNK2A1KMT2A | |
| SCHEMBL17186412 | 0.82 | FAAH (0.48) | CSNK2BCSNK2A1KMT2AFAAH | |
| SCHEMBL7423431 | 0.82 | FAAH (0.48) | CSNK2BCSNK2A1KMT2AFAAH | |
| SCHEMBL1153166 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2AFAAH | |
| SCHEMBL4515997 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2AFAAH | |
| SCHEMBL2370627 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2AFAAH | |
| SCHEMBL3305638 | 0.82 | KDM4E (0.45) | PDE4BOXTRKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385061-B2 | Medicarpin, its derivatives, manufacturing method thereof | PHYTOHEALTH CORPORATION (TW) | 2019-08-20 | — | — | US | disclosed |
| US-20180086772-A1 | MEDICARPIN, ITS DERIVATIVES, MANUFACTURING METHOD THEREOF | PHYTOHEALTH CORPORATION (TW) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086772-A1 | MEDICARPIN, ITS DERIVATIVES, MANUFACTURING METHOD THEREOF | SHARPIN, TIPARP, MYADM | PDE4B 752/4885OXTR 4805/4885MTNR1A 640/4885 |
| US-10385061-B2 | Medicarpin, its derivatives, manufacturing method thereof | SHARPIN, ATP6V1B1, REN | PDE4B 658/4885OXTR 4715/4885MTNR1A 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.